Sava Technologies builds a proprietary multi-molecule biosensor powering a pain-free wearable that delivers real-time molecular insights to a smartphone. The device has demonstrated accurate glucose readings for up to 10 days in early clinical data from a 50-patient study (first 25 participants). Sava aims to address key CGM barriers—pain, cost and accessibility—and to expand beyond glucose to multi-analyte sensing for preventative and personalised healthcare. The company plans a pivotal study next year and is working toward regulatory approval and commercialisation while scaling automated manufacturing to meet launch volumes. Founded in 2019 and based in London, Sava is also pursuing interest from athletes and health-conscious consumers as it targets the global wearables market. Sava is a London, UK-based consumer and medical device company developing a wearable biosensor platform that can detect molecules just under the skin. Its novel microsensor technology monitors biomarkers in real time, starting with glucose. The company recently gained MHRA approval to proceed with clinical trials in patients with diabetes. An upcoming clinical study is scheduled to start with investigators from the Universities of Oxford and Cambridge. Sava plans to use the $8M Seed to expand its team, design its product line with manufacturing capability, and demonstrate the platform’s clinical performance. The company was founded by Renato Circi and Rafael Michali.

Total raised

$27M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2025